Based on the Madrigal Pharmaceuticals Inc stock forecast from 13 analysts, the average analyst target price for Madrigal Pharmaceuticals Inc is USD 304.43 over the next 12 months. Madrigal Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Madrigal Pharmaceuticals Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Madrigal Pharmaceuticals Inc’s stock price was USD 288.58. Madrigal Pharmaceuticals Inc’s stock price has changed by -17.71% over the past week, +37.11% over the past month and +63.35% over the last year.
No recent analyst target price found for Madrigal Pharmaceuticals Inc
No recent average analyst rating found for Madrigal Pharmaceuticals Inc
Company Overview Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. Read Less
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone recept...Read More
Frequently Asked Questions About Madrigal Pharmaceuticals Inc (MDGL) Stock
Based on ratings from 13 analysts Madrigal Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 13 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on MDGL's stock to indicate if its a good dividend stock.
Based on targets from 13 analysts, the average taret price for MDGL is USD 304.43 over the next 12 months. The maximum analyst target price is USD 400 while the minimum anlayst target price is USD 90.
Unfortunately we do not have enough data on MDGL's stock to indicate if its overvalued.
The last closing price of MDGL's stock was USD 288.58.
The most recent market capitalization for MDGL is USD 6.29B.
Based on targets from 13 analysts, the average taret price for MDGL is projected at USD 304.43 over the next 12 months.
This means that MDGL's stock price may go up by +5.49% over the next 12 months.
We can't find any ETFs which contains Madrigal Pharmaceuticals Inc's stock.
As per our most recent records Madrigal Pharmaceuticals Inc has 376 Employees.
Madrigal Pharmaceuticals Inc's registered address is Four Tower Bridge, West Conshohocken, PA, United States, 19428.
You can get more information about it from Madrigal Pharmaceuticals Inc's website at https://www.madrigalpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Madrigal Pharmaceuticals Inc (MDGL) Stock
Based on ratings from 13 analysts Madrigal Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 13 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on MDGL's stock to indicate if its a good dividend stock.
Based on targets from 13 analysts, the average taret price for MDGL is USD 304.43 over the next 12 months. The maximum analyst target price is USD 400 while the minimum anlayst target price is USD 90.
Unfortunately we do not have enough data on MDGL's stock to indicate if its overvalued.
The last closing price of MDGL's stock was USD 288.58.
The most recent market capitalization for MDGL is USD 6.29B.
Based on targets from 13 analysts, the average taret price for MDGL is projected at USD 304.43 over the next 12 months.
This means that MDGL's stock price may go up by +5.49% over the next 12 months.
We can't find any ETFs which contains Madrigal Pharmaceuticals Inc's stock.
As per our most recent records Madrigal Pharmaceuticals Inc has 376 Employees.
Madrigal Pharmaceuticals Inc's registered address is Four Tower Bridge, West Conshohocken, PA, United States, 19428.
You can get more information about it from Madrigal Pharmaceuticals Inc's website at https://www.madrigalpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MDGL !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
